Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GCK | P35557 | 1/20 | 0.50 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681119 | 0.86 | MAPT (0.56) | MAPTL3MBTL1GCKHCAR3XDH | |
| SCHEMBL7316232 | 0.80 | NFE2L2 (0.62) | L3MBTL1GCKNFE2L2 | |
| SCHEMBL12420774 | 0.80 | HRH3 (0.53) | CXCR1CXCR2 | |
| SCHEMBL2195324 | 0.80 | KDM4C (0.54) | MAPTL3MBTL1GCKALOX5PTGES | |
| SCHEMBL7405208 | 0.79 | GPR119 (0.52) | MAPT | |
| SCHEMBL25233954 | 0.78 | KDM2B (0.42) | GCKALOX5PTGESPTGS2PPARG | |
| SCHEMBL795937 | 0.78 | MAPT (0.61) | MAPTL3MBTL1HCAR3XDH | |
| SCHEMBL2195636 | 0.77 | HPGD (0.47) | L3MBTL1IDO1NFE2L2 | |
| SCHEMBL796604 | 0.77 | MAPT (0.51) | MAPTL3MBTL1CXCR1CXCR2HCAR3 | |
| SCHEMBL4767310 | 0.77 | MAPT (0.51) | MAPTL3MBTL1CXCR1CXCR2HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | MAPT 2291/4885L3MBTL1 4818/4885GCK 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.